191 related articles for article (PubMed ID: 22795544)
1. Anti-CD20 multivalent HPMA copolymer-Fab' conjugates for the direct induction of apoptosis.
Chu TW; Yang J; Kopeček J
Biomaterials; 2012 Oct; 33(29):7174-81. PubMed ID: 22795544
[TBL] [Abstract][Full Text] [Related]
2. Biological activity of anti-CD20 multivalent HPMA copolymer-Fab' conjugates.
Johnson RN; Kopečková P; Kopeček J
Biomacromolecules; 2012 Mar; 13(3):727-35. PubMed ID: 22288884
[TBL] [Abstract][Full Text] [Related]
3. Drug-free macromolecular therapeutics: Impact of structure on induction of apoptosis in Raji B cells.
Zhang L; Fang Y; Yang J; Kopeček J
J Control Release; 2017 Oct; 263():139-150. PubMed ID: 28024916
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and evaluation of multivalent branched HPMA copolymer-Fab' conjugates targeted to the B-cell antigen CD20.
Johnson RN; Kopecková P; Kopecek J
Bioconjug Chem; 2009 Jan; 20(1):129-37. PubMed ID: 19154157
[TBL] [Abstract][Full Text] [Related]
5. Combination chemotherapy and photodynamic therapy with fab' fragment targeted HPMA copolymer conjugates in human ovarian carcinoma cells.
Hongrapipat J; Kopecková P; Liu J; Prakongpan S; Kopecek J
Mol Pharm; 2008; 5(5):696-709. PubMed ID: 18729468
[TBL] [Abstract][Full Text] [Related]
6. Simultaneous crosslinking of CD20 and CD38 receptors by drug-free macromolecular therapeutics enhances B cell apoptosis in vitro and in vivo.
Tommy Gambles M; Li J; Christopher Radford D; Sborov D; Shami P; Yang J; Kopeček J
J Control Release; 2022 Oct; 350():584-599. PubMed ID: 36037975
[TBL] [Abstract][Full Text] [Related]
7. Polymerizable Fab' antibody fragments for targeting of anticancer drugs.
Lu ZR; Kopecková P; Kopecek J
Nat Biotechnol; 1999 Nov; 17(11):1101-4. PubMed ID: 10545917
[TBL] [Abstract][Full Text] [Related]
8. Immunogenicity of coiled-coil based drug-free macromolecular therapeutics.
Kverka M; Hartley JM; Chu TW; Yang J; Heidchen R; Kopeček J
Biomaterials; 2014 Jul; 35(22):5886-96. PubMed ID: 24767787
[TBL] [Abstract][Full Text] [Related]
9. HPMA copolymer conjugates with reduced anti-CD20 antibody for cell-specific drug targeting. I. Synthesis and in vitro evaluation of binding efficacy and cytostatic activity.
Etrych T; Strohalm J; Kovár L; Kabesová M; Ríhová B; Ulbrich K
J Control Release; 2009 Nov; 140(1):18-26. PubMed ID: 19632282
[TBL] [Abstract][Full Text] [Related]
10. Characterization of a new humanized anti-CD20 monoclonal antibody, IMMU-106, and Its use in combination with the humanized anti-CD22 antibody, epratuzumab, for the therapy of non-Hodgkin's lymphoma.
Stein R; Qu Z; Chen S; Rosario A; Shi V; Hayes M; Horak ID; Hansen HJ; Goldenberg DM
Clin Cancer Res; 2004 Apr; 10(8):2868-78. PubMed ID: 15102696
[TBL] [Abstract][Full Text] [Related]
11. Multimodality imaging of coiled-coil mediated self-assembly in a "drug-free" therapeutic system.
Zhang R; Yang J; Chu TW; Hartley JM; Kopeček J
Adv Healthc Mater; 2015 May; 4(7):1054-65. PubMed ID: 25612325
[TBL] [Abstract][Full Text] [Related]
12. Preparation and biological evaluation of polymerizable antibody Fab' fragment targeted polymeric drug delivery system.
Lu ZR; Shiah JG; Kopecková P; Kopecek J
J Control Release; 2001 Jul; 74(1-3):263-8. PubMed ID: 11489505
[TBL] [Abstract][Full Text] [Related]
13. Star structure of antibody-targeted HPMA copolymer-bound doxorubicin: a novel type of polymeric conjugate for targeted drug delivery with potent antitumor effect.
Kovár M; Strohalm J; Etrych T; Ulbrich K; Ríhová B
Bioconjug Chem; 2002; 13(2):206-15. PubMed ID: 11906257
[TBL] [Abstract][Full Text] [Related]
14. Anti-Lymphoma Efficacy Comparison of Anti-Cd20 Monoclonal Antibody-Targeted and Non-Targeted Star-Shaped Polymer-Prodrug Conjugates.
Lidický O; Janoušková O; Strohalm J; Alam M; Klener P; Etrych T
Molecules; 2015 Nov; 20(11):19849-64. PubMed ID: 26556320
[TBL] [Abstract][Full Text] [Related]
15. A Two-Step Pretargeted Nanotherapy for CD20 Crosslinking May Achieve Superior Anti-Lymphoma Efficacy to Rituximab.
Chu TW; Zhang R; Yang J; Chao MP; Shami PJ; Kopeček J
Theranostics; 2015; 5(8):834-46. PubMed ID: 26000056
[TBL] [Abstract][Full Text] [Related]
16. Mechanisms of cytotoxicity in human ovarian carcinoma cells exposed to free Mce6 or HPMA copolymer-Mce6 conjugates.
Tijerina M; Kopecková P; Kopecek J
Photochem Photobiol; 2003 Jun; 77(6):645-52. PubMed ID: 12870851
[TBL] [Abstract][Full Text] [Related]
17. Antilymphoma effects of anti-HLA-DR and CD20 monoclonal antibodies (Lym-1 and Rituximab) on human lymphoma cells.
Liu C; DeNardo G; Tobin E; DeNardo S
Cancer Biother Radiopharm; 2004 Oct; 19(5):545-61. PubMed ID: 15650447
[TBL] [Abstract][Full Text] [Related]
18. Human Serum Albumin-Based Drug-Free Macromolecular Therapeutics: Apoptosis Induction by Coiled-Coil-Mediated Cross-Linking of CD20 Antigens on Lymphoma B Cell Surface.
Zhang L; Fang Y; Li L; Yang J; Radford DC; Kopeček J
Macromol Biosci; 2018 Nov; 18(11):e1800224. PubMed ID: 30259654
[TBL] [Abstract][Full Text] [Related]
19. HPMA copolymer-anticancer drug-OV-TL16 antibody conjugates. 1. influence of the method of synthesis on the binding affinity to OVCAR-3 ovarian carcinoma cells in vitro.
Omelyanenko V; Kopecková P; Gentry C; Shiah JG; Kopecek J
J Drug Target; 1996; 3(5):357-73. PubMed ID: 8866655
[TBL] [Abstract][Full Text] [Related]
20. Suppression of Rituximab-resistant B-cell lymphoma with a novel multi-component anti-CD20 mAb nanocluster.
Li H; Zhang G; Jiang C; Zhang F; Ke C; Zhao H; Sun Y; Zhao M; Chen D; Zhu X; Zhang L; Li B; Dai J; Li W
Oncotarget; 2015 Sep; 6(27):24192-204. PubMed ID: 26284588
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
